Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening
Sponsor: National Taiwan University Hospital
Summary
This study aims to evaluate the effectiveness of an artificial intelligence (AI)-assisted screening system in ophthalmic diagnosis. Using AI-based fundus photography, the system will assist physicians in diagnosing three common eye diseases: age-related macular degeneration and diabetic retinopathy (DR). The AI system will analyze fundus images from participants and rapidly generate detection results for ophthalmologists' reference in making final diagnoses and clinical decisions. The study will assess the clinical benefits of the AI-assisted diagnostic system, providing scientific evidence to enhance the efficiency of ophthalmic disease diagnosis and treatment.
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
1000
Start Date
2025-06-02
Completion Date
2027-12-31
Last Updated
2025-06-22
Healthy Volunteers
No
Interventions
The VeriSee AI-assisted diagnostic system
VeriSee AMD, VeriSee DR, and VeriSee GLC are AI-based medical software devices designed for screening age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma, respectively. These systems utilize advanced AI algorithms to analyze color fundus photography images for disease assessment. By installing the software on a computer, the system can evaluate image quality, predict disease conditions, and instantly provide results to clinical physicians, serving as a diagnostic aid.
Data collection from the patient's clinical history
Data collection from the patient's clinical history was conducted because the VeriSee AI-assisted diagnostic system was not used.
Locations (1)
National Taiwan University Hospital
Taipei, Taiwan, Taiwan